Evidence map›Paper›PMID 27688036›Full record

ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2017

Effects of an endothelin receptor antagonist, Macitentan, on right ventricular substrate utilization and function in a Sugen 5416/hypoxia rat model of severe pulmonary arterial hypertension.

Katarzyna Drozd, Ali Ahmadi, Yupu Deng, Baohua Jiang, Julia Petryk, Stephanie Thorn, Duncan Stewart, Rob Beanlands, Robert A deKemp, Jean N DaSilva and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Reply to BogaardAmerican journal of respiratory and critical care medicine · 2019
    Article
  9. Article
  10. Molecular Imaging of the Heart.Comprehensive Physiology · 2019
    Review
  11. Review
  12. Review
  13. Review
  14. Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice.European respiratory review : an official journal of the European Respiratory Society · 2017
    Review
  15. Assessment of right ventricular metabolism: An emerging tool for monitoring pulmonary artery hypertension.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017
    Article
  16. Dual ETPulmonary circulation
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Katarzyna DrozdDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada.
Ali AhmadiDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada.
Yupu DengOttawa Hospital Research Institute, 1053 Carling Ave, Ottawa, ON, Canada.
Baohua JiangOttawa Hospital Research Institute, 1053 Carling Ave, Ottawa, ON, Canada.
Julia PetrykDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada.
Stephanie ThornDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada.
Duncan StewartOttawa Hospital Research Institute, 1053 Carling Ave, Ottawa, ON, Canada.
Rob BeanlandsDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada.
Robert A deKempDepartment of Cardiac Imaging, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Jean N DaSilvaDepartment of Radiology, Radio-Oncology and Nuclear Medicine, University of Montreal, Montreal, QC, Canada.
Lisa M MielniczukDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada. lmielniczuk@ottawaheart.ca.
University of Ottawa · CAOttawa Hospital Research InstituteOttawa Hospital · CAUniversité de Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAltered myocardial energy metabolism has been linked to worsening of RV function in pulmonary arterial hypertension (PAH). The aim of this study was to evaluate RV glucose and fatty acid metabolism in vivo in a rat model of PAH using positron emission tomography (PET) and investigate the effects of Macitentan on RV substrate utilization.

methodsPAH was induced in male Sprague-Dawley rats by a single subcutaneous injection of Sugen 5416 (20 mg/kg) followed by 3 weeks of hypoxia (10% oxygen). At week 5 post-injection, the PAH rats were randomized to Macitentan (30 mg/kg daily) treatment or no treatment. Substrate utilization was serially assessed 5 and 8 weeks post-injection with 2-[

resultsPAH induction resulted in a 2.5-fold increase in RV FDG uptake (standardized uptake value (SUV) of normal control: 1.6 ± 0.4, week 5: 4.1 ± 1.9, week 8: 4.0 ± 1.6, P < 0.05 for all groups vs. control). RV FTHA showed twofold increased uptake at week 5 (SUV control: 1.50 ± 0.39, week 5: 3.06 ± 1.10, P = 0.03). Macitentan significantly decreased RV FDG uptake at 8 weeks (SUV: 2.5 ± 0.9, P = 0.04), associated with improved RV ejection fraction and reduced RV systolic pressure, while FTHA uptake was maintained.

conclusionPAH is associated with metabolic changes in the RV, characterized by a marked increase in FDG and FTHA uptake. Macitentan treatment reduced PAH severity and was associated with a decrease in RV FDG uptake and improved RV function.

Indexed as

AnimalsDisease Models, AnimalEndothelin Receptor AntagonistsFatty AcidsGlucoseHeart VentriclesHypertension, PulmonaryHypoxiaMalePyrimidinesRatsRats, Sprague-DawleySulfonamidesVentricular Function, RightEndothelin Receptor AntagonistsFatty AcidsGlucosemacitentanPyrimidinesSulfonamidesFatty acid imagingfluorodeoxyglucose (FDG)heart failuremetabolismmicroPET imagingPET

Identifiers

PMID27688036
OpenAlexW1966041551

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.